ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Cosentyx?displays a 72 percent reduced arthritis flare risk EuropeanPharmaceuticalReview
November 11, 2021Novartis has announced new analyses from the two-year positive Phase III JUNIPERA study, which demonstrated the treatment response of Cosentyx? (secukinumab?)... -
Novartis Presents Positive Results from JUNIPERA Study Supporting Cosentyx as a Treatment in a JIA Population americanpharmaceuticalreview
June 04, 2021Novartis, a leader in rheumatology and immuno-dermatology, announced 2-year positive results from the Phase III JUNIPERA study, demonstrating that Cosentyx? (secukinumab) significantly delayed time to flare vs placebo (P<.001) in pediatric patients ... -
Janssen Submits sBLA for SIMPONI ARIA for Juvenile Arthritis americanpharmaceuticalreview
April 26, 2020The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of two supplemental Biologics License Applications (sBLA).
Pharma Sources Insight January 2025
